BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 30522949)

  • 1. An Organoid-Based Preclinical Model of Human Gastric Cancer.
    Steele NG; Chakrabarti J; Wang J; Biesiada J; Holokai L; Chang J; Nowacki LM; Hawkins J; Mahe M; Sundaram N; Shroyer N; Medvedovic M; Helmrath M; Ahmad S; Zavros Y
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):161-184. PubMed ID: 30522949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human gastric cancer modelling using organoids.
    Seidlitz T; Merker SR; Rothe A; Zakrzewski F; von Neubeck C; Grützmann K; Sommer U; Schweitzer C; Schölch S; Uhlemann H; Gaebler AM; Werner K; Krause M; Baretton GB; Welsch T; Koo BK; Aust DE; Klink B; Weitz J; Stange DE
    Gut; 2019 Feb; 68(2):207-217. PubMed ID: 29703791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis.
    Nanki K; Toshimitsu K; Takano A; Fujii M; Shimokawa M; Ohta Y; Matano M; Seino T; Nishikori S; Ishikawa K; Kawasaki K; Togasaki K; Takahashi S; Sukawa Y; Ishida H; Sugimoto S; Kawakubo H; Kim J; Kitagawa Y; Sekine S; Koo BK; Kanai T; Sato T
    Cell; 2018 Aug; 174(4):856-869.e17. PubMed ID: 30096312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids.
    Elbadawy M; Hayashi K; Ayame H; Ishihara Y; Abugomaa A; Shibutani M; Hayashi SM; Hazama S; Takenouchi H; Nakajima M; Tsunedomi R; Suzuki N; Nagano H; Shinohara Y; Kaneda M; Yamawaki H; Usui T; Sasaki K
    Biomed Pharmacother; 2021 Oct; 142():112043. PubMed ID: 34411919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
    Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
    Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Maru Y; Tanaka N; Itami M; Hippo Y
    Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells.
    Kijima T; Nakagawa H; Shimonosono M; Chandramouleeswaran PM; Hara T; Sahu V; Kasagi Y; Kikuchi O; Tanaka K; Giroux V; Muir AB; Whelan KA; Ohashi S; Naganuma S; Klein-Szanto AJ; Shinden Y; Sasaki K; Omoto I; Kita Y; Muto M; Bass AJ; Diehl JA; Ginsberg GG; Doki Y; Mori M; Uchikado Y; Arigami T; Avadhani NG; Basu D; Rustgi AK; Natsugoe S
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):73-91. PubMed ID: 30510992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.
    Li J; Xu H; Zhang L; Song L; Feng D; Peng X; Wu M; Zou Y; Wang B; Zhan L; Hua G; Zhan X
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2637-2647. PubMed ID: 31598791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.
    Yan HHN; Siu HC; Law S; Ho SL; Yue SSK; Tsui WY; Chan D; Chan AS; Ma S; Lam KO; Bartfeld S; Man AHY; Lee BCH; Chan ASY; Wong JWH; Cheng PSW; Chan AKW; Zhang J; Shi J; Fan X; Kwong DLW; Mak TW; Yuen ST; Clevers H; Leung SY
    Cell Stem Cell; 2018 Dec; 23(6):882-897.e11. PubMed ID: 30344100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulators of the Nrf2 Signaling Pathway Enhance the Cytotoxic Effect of Standard Chemotherapeutic Drugs on Organoids of Metastatic Colorectal Cancer.
    Razumovskaya AV; Silkina MO; Nikulin SV; Tonevitsky AG; Alekseev BY
    Bull Exp Biol Med; 2024 Mar; 176(5):703-708. PubMed ID: 38724815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
    Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
    Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture.
    Elbadawy M; Usui T; Mori T; Tsunedomi R; Hazama S; Nabeta R; Uchide T; Fukushima R; Yoshida T; Shibutani M; Tanaka T; Masuda S; Okada R; Ichikawa R; Omatsu T; Mizutani T; Katayama Y; Noguchi S; Iwai S; Nakagawa T; Shinohara Y; Kaneda M; Yamawaki H; Sasaki K
    Cancer Sci; 2019 Sep; 110(9):2806-2821. PubMed ID: 31254429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment and application of gastric and gastric cancer organoids].
    Fan S; Yin J; Wang M; Guan W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1315-1320. PubMed ID: 30506544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors.
    Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q
    Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.